Answers are grounded in this paper and cite their sources.
Portal hypertension is the main pathophysiology of chronic liver disease. The severity of portal hypertension depends on portal venous pressure, which is associated with various manifestations such as gastroesophageal varices, portal hypertensive gastropathy, ascites, and hepatic encephalopathy. As portal pressure is also a significant prognostic factor for patients, it is recognized as a key parameter in medical care. Hepatic venous pressure gradient (HVPG) is defined as the difference between wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP), both of which are measured by hepatic venous catheterization. The HVPG is a useful clinical marker, used as an alternative to direct measurement of portal pressure, to determine the degree and severity of portal hypertension and chronic liver disease, decide management direction, and estimate the prognosis. Many noninvasive methods have been developed to determine HVPG to reduce the burden on patients, such as elastography using various imaging methods, Doppler parameters, contrast-enhanced ultrasound findings, and serum-based markers. However, as it is difficult to predict the precise HVPG value, hepatic venous catheterization is still the gold standard for obtaining HVPG despite its invasiveness. The jugular venous approach or femoral venous approach can be used available, as both these veins connect to the hepatic vein through the inferior vena cava (IVC). In general, the jugular venous approach may be preferred over the femoral venous approach because of easier access due to the obtuse angle between the hepatic vein and IVC. However, it should be noted that advancement of the guidewire from a jugular vein is not necessarily easy under the influence of heartbeat or in the case of marked cardiomegaly. As it is an angiographic procedure, a basic technique to handle the guidewire and catheter is required. First, it is important to select the main branch of the right hepatic vein, and FHVP is simply measured using a catheter. Although there are two methods to assess WHVP, the occlusion-balloon method, and the end-hole catheter method, the former is now considered the standard due to few errors in the measurement of pressure. The most frequently used balloon catheter for HVPG measurement in Japan is the standard type (TERUMO) with balloon size of 9 mm (5Fr). It is important to place the balloon catheter not too far into the hepatic vein (FHVP measurement in the hepatic vein within 2–3 cm of its confluence with the IVC),1 and hepatic venous blood flow can be temporally controlled by balloon inflation. Complete occlusion is confirmed by test injection of a small amount of contrast material, and WHVP can then be measured. CO2 can be used as a contrast source alternative to iodinated contrast material because of its safety and reliability with better collateral filling (Figure 1A). HVPG is obtained from the difference between WHVP and FHVP. The measurement should be conducted after the stabilization of pressure conditions, a period of about 1 min for WHVP and 15 s for FHVP. The data is recorded by the tracing for 45–60 s with the appropriate speed of 5 mm/s (up to 7.5 mm/s),1 and continuous recording is needed when deflating the balloon to reconfirm the FHVP. Heterogeneity/variation of HVPG: Keiding et al. measured HVPG in two separate hepatic veins in 102 cirrhosis patients and 27 controls (patients with no liver disease).2 They found that there was a certain difference between the first vein measurement and second vein measurement, and the difference was larger in cirrhosis patients than in controls. In addition, >60% of patients showed pressure with a wide-range difference from 4 to 34 mmHg. Some parts may be physiological variations, but there is a definite variation in HVPG, and care should be taken for this heterogeneity. Variations in HVPG also increase with deep sedation using propofol and remifentanil, which needs to be recognized as the pitfall of hepatic venous catheterization. Presence of veno-venous communication: Hepatic veno-venous communication is the connection between different hepatic veins (Figure 1B). The WHVP does not reflect portal pressure in patients with hepatic veno-venous communications. This is logically acceptable because the presence of veno-venous communications has a suppressive effect on the actual pressure. How to do against the pitfall: It is important to repeat the measurements at least three times to confirm the reproducibility of the data. Particularly, in the case of veno-venous communications, the catheter needs to be moved to the distal position, or to another hepatic vein to minimize the measurement error. Only minor complications can occur during or after hepatic venous catheterization, such as pain at the puncture site (cervical or femoral), vagal reaction, and transient arrhythmia caused by guidewire movement. Needless to say, damage to the surrounding (artery or nerve) should be avoided when performing venous puncture. In addition, care should be taken against the allergy and/or adverse events caused by iodinated contrast material as contrast enhancement is necessary to ensure complete occlusion by balloon inflation in the hepatic vein and to evaluate the vascular/sinusoidal appearance. CO2 can be used as a contrast source alternative to iodinated contrast materials. Pressure data obtained from hepatic venous catheterization is useful for differential diagnosis of portal hypertension; prehepatic portal hypertension with normal FHVP, normal WHVP and normal HVPG, hepatic portal hypertension with normal FHVP, high WHVP and normal/high HVPG, and posthepatic portal hypertension with high FHVP, normal/high WHVP and normal/high HVPG. Furthermore, hepatic portal hypertension can be classified into three subgroups, presinusoidal, sinusoidal, and postsinusoidal portal hypertension. Due to the pathophysiological reasons, HVPG does not reflect portal pressure in cases with presinusoidal portal hypertension and/or advanced portal vein thrombosis. This is the disadvantage of hepatic venous catheterization, which fails to estimate accurate portal pressure, but almost normal HVPG can be applied for the detection of presinusoidal blockage. In patients with primary biliary cholangitis (PBC), the pathophysiology of portal hypertension is considered to vary according to the development of the disease, early stage with the presinusoidal portal hypertension, and shifting to the sinusoidal portal hypertension as the disease progresses. However, a recent study suggests that sinusoidal blockage is the underlying pathophysiology even in the early-stage PBC, proved by the retrograde demonstration of the intrahepatic portal vein by hepatic venous catheterization, and veno-venous communication in the liver is responsible for alleviated HVPG.3 The pathophysiology of PBC needs further evaluation in a larger patient population. Long-term therapy with nonselective beta-adrenergic blockers, with or without organic nitrates, reduces the risk of first or recurrent variceal bleeding. A decrease of HVPG < 12 mmHg or at least 20% from baseline indicates “response to medication,” which offers the reduction of the risk of rebleeding or death. Furthermore, recent studies reported that hemodynamic response-guided therapy using HVPG effectively protects patients from rebleeding,4 enhancing the benefit of the application of HVPG for the therapeutic direction of variceal bleeding. A retrograde venogram under balloon occlusion demonstrates enhancement in the hepatic vein branches and hepatic sinusoid. Appearances on the venogram are useful for differentiating between cirrhosis and idiopathic portal hypertension (IPH), the latter represents noncirrhotic presinusoidal portal hypertension. In the former, in general, veno-venous communication is rare, with wide angles between veins and tributaries and irregular stenoses of large veins and branches at various levels. Spotty sinusoidal filling and retrograde detection of the intrahepatic portal vein are frequently demonstrated (Figure 1C). Meanwhile, enhancement findings of IPH are quite different from those of cirrhosis. Veno-venous communication is common, and the following findings strongly suggest IPH: narrower angles between large veins and their tributaries, smooth and wavy middle-sized to large branches (“weeping willow” appearance), homogeneous sinusoidal filling, and minimal to absent filling of the portal venous system (Figure 1D). Thus, hepatic venous catheterization provides useful information for diagnosing IPH. However, the application needs to be carefully decided because of the invasiveness with the risk of various complications. HVPG is a definitive parameter for deciding the management direction and predicting short- and long-term outcomes in patients with portal hypertension. Although there are a number of noninvasive markers to estimate HVPG, measurement of pressure by hepatic venous catheterization is the gold standard. In addition, it is effective in differentiating between cirrhosis and IPH. Based on the backgrounds, Sun et al. reported well tolerance and the safety of the technique in the recently performed prospective international multicenter study5; the technical success of HVPG measurement in all 271 patients with single HVPG measurement in 52% of them, and the complication rate of 0.4%. As for the tolerance of hepatic venous catheterization, the postoperative pain was significantly less than the preoperative expected pain (p < 0.001) or the intraoperative pain (p < 0.001), and the intraoperative pain was also significantly less than the preoperative expected pain (p = 0.036). It may be the first report focusing on the unique aspect of hepatic venous catheterization. However, there are some concerns in the study. First, although it may be an international study, the patient population is Asian dominant, being much biased toward China. Second, management and interpretation of clinical symptoms may not be well organized because pain is not classified as a complication, and the questionnaire method for patients with hepatic encephalopathy is not clearly mentioned. In addition, they also reported the low acceptance of hepatic venous catheterization; merely half of the patients did not fully understand the value of HVPG measurement (a little 39.5%, nothing 10.0%), and almost 40% of patients regarded that HVPG measurement helps a little (35.1%) or nothing (4.1%). Specific measures to promote the understanding of the patients need to be further discussed. In addition, enlightenment activities for the spread and the standardization of the technique are required. In conclusion, hepatic venous catheterization is safe and can be performed under minimum radiation exposure. Also, the use of iodinated contrast material is not mandatory when using CO2, which is safe and effective. Against the invasive aspect, clinicians need to recognize the benefits of HVPG and should encourage the practical application of hepatic venous catheterization. None. The author declares no conflict of interest. This article does not contain any studies with human participants or animals performed by any of the authors.
No takes yet. Share an insight, caveat, or question.
Hitoshi Maruyama (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: